Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study

Ophthalmology

Volumn 118, Issue 5, 2011, Pages 831-839

  Schmidt Erfurth, Ursula ^a   Eldem, Bora ^b   Guymer, Robyn ^c   Korobelnik, Jean Franois ^d   Schlingemann, Reinier O ^e   Axer Siegel, Ruth ^f   Wiedemann, Peter ^g   Simader, Christian ^h   Gekkieva, Margarita ⁱ   Weichselberger, Andreas ⁱ  

^a UNIVERSITY OF VIENNA   (Austria)

^b HACETTEPE UNIVERSITY   (Turkey)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d HÔPITAL PELLEGRIN   (France)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f RABIN MEDICAL CENTER   (Israel)

^g UNIVERSITY OF LEIPZIG   (Germany)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ANGINA PECTORIS; ARTERIOTHROMBOEMBOLISM; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; INTRAOCULAR PRESSURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT DURATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79955631484     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2010.09.004     Document Type: Article

References (13)

1. B.A. Keyt, L.T. Berleau, and H.V. Nguyen The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency J Biol Chem 271 1996 7788 7795 (Pubitemid 26111064)
2. N. Ferrara, R.D. Mass, C. Campa, and R. Kim Targeting VEGF-A to treat cancer and age-related macular degeneration Annu Rev Med 58 2007 491 504 (Pubitemid 46706529)
3. J.S. Penn, A. Madan, and R.B. Caldwell Vascular endothelial growth factor in eye disease Prog Retin Eye Res 27 2008 331 371
4. M. Waisbourd, A. Loewenstein, M. Goldstein, and I. Leibovitch Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration Drugs Aging 24 2007 643 662
5. S. Grisanti, and O. Tatar The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration Prog Retin Eye Res 27 2008 372 390
6. N. Ferrara, L. Damico, and N. Shams Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870 (Pubitemid 44547437)
7. J. Lowe, J. Araujo, and J. Yang Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo Exp Eye Res 85 2007 425 430 (Pubitemid 47542265)
8. Y. Chen, C. Wiesmann, and G. Fuh Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen J Mol Biol 293 1999 865 881 (Pubitemid 29527672)
9. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431 (Pubitemid 44511557)
10. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444 (Pubitemid 44511558)
11. D.M. Brown, M. Michels, P.K. Kaiser ANCHOR Study Group Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 2009 57 65
12. C.D. Regillo, D.M. Brown, P. Abraham PIER Study Group Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2008 239 248
13. P. Mitchell, J.F. Korobelnik, and P. Lanzetta Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials Br J Ophthalmol 94 2010 2 13